ASP Isotopes Inc. Common Stock
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul Elliot Mann
- Full Time Employees
- 271
- Sector
- Basic Materials
- Industry
- Chemicals
- Address
- 2200 Ross Avenue Dallas TX United States of America 75201
- IPO Date
- Nov 10, 2022
- CIK
- 0001921865
- Website
- aspisotopes.com
- Similar Companies
- Business
- ASP Isotopes Inc. (ASPI) operates as a development-stage advanced materials company focused on developing proprietary technologies and processes to produce and enrich isotopes for nuclear medicine, green energy generation, semiconductors, quantum computing, and related industries; core offerings encompass the Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE) technologies for separating isotopes such as Carbon-14 (C-14), Molybdenum-100 (Mo-100), Molybdenum-98 (Mo-98), Silicon-28 (Si-28), and Ytterbium-176 (Yb-176) used in pharmaceuticals, agrochemicals, nuclear medical imaging, and high-assay low-enriched uranium (HALEU), Lithium-6, and Chlorine-37 for advanced nuclear fuels; the company also provides nuclear medicine services through its 51% majority stake in PET Labs (Pty) Ltd., a leader in South Africa and sub-Saharan Africa. Incorporated in Delaware in September 2021 with principal executive offices in Washington, DC, ASP Isotopes maintains enrichment facilities in South Africa and conducts research and development across two main segments: Nuclear Fuels and Specialist Isotopes and Related Services, targeting healthcare, technology, and energy markets primarily in the United States, South Africa, and the United Kingdom. Recent developments include the early commissioning of a Quantum Enrichment facility for Ytterbium-176 and commencement of commercial production for enriched Carbon-14 and Silicon-28 in 2025; expansion through three new facilities and strategic partnerships, such as a Series Seed funding investment of $5 million in IsoBio, Inc. in July 2025 to advance antibody-isotope conjugates for cancer treatment with potential manufacturing via PET Labs; an announced agreement for the potential acquisition of Renergen Limited to create a global critical materials leader; acquisition of intellectual property assets and a 30 SWU facility by subsidiary Quantum Leap Energy LLC in October 2025; and a return of Executive Chairman and CEO Paul Mann from temporary leave in December 2025.
ASP Isotopes Targets 2026 Deliveries as Helium, Radiopharmacy Expansion Gains Speed
ASP Isotopes Inc. Announces that Renergen Limited's Subsidiary has Entered into a Take-or-Pay Contract for the Supply of Liquified Natural Gas to Be Produced at the Virginia Gas Project in South Africa
ASP Isotopes to Participate in Citi's 2026 Natural Resources Conference
Aeternum Health Announces Change in Strategy, New Management, and Updates Investors on Progress
ASP Isotopes Issues Letter to Shareholders
ASP Isotopes to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
ASP Isotopes to Hold Capital Markets Day on September 8
ASP Isotopes Inc. (ASPI) Discusses Noble Africa's Merger Plans and Strategy to Become a Publicly Traded Helium Platform Transcript
ASP Isotopes Maps Noble Africa Listing as Helium Project Nears Production
ASP Isotopes Announces Quantum Leap Energy Research Agreement with Texas A&M Engineering Experiment Station to Advance Uranium Conversion Technology
Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
ASP Isotopes Announces Agreements to Exchange Certain QLE Convertible Notes for ASPI Common Stock
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing
ASP Isotopes Stock Surges After Silicon-28 Facility Restart
ASP Isotopes Implements Engineering Enhancements to Silicon-28 Enrichment Facility; Successfully Restarts First 18 Stages of Silicon-28 Enrichment Facility; Commercial Shipments of Enriched Silicon-28 Expected to Commence in Q3 2026
ASP Isotopes Announces HALEU Supply MOU Through Subsidiary, Shares Move Higher